The stock price of Bristol-Myers Squibb Co (NYSE: BMY) has dropped by -0.16 compared to previous close of 56.38. Despite this, the company has seen a gain of 0.82% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-19 that This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to exceed $190 billion by 2028. Every year, regulatory agencies approve dozens of biosimilars and brand-name drugs, so Seeking Alpha readers should be careful when making decisions.
Is It Worth Investing in Bristol-Myers Squibb Co (NYSE: BMY) Right Now?
Additionally, the 36-month beta value for BMY is 0.45. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 4 rating it as “overweight,” 17 rating it as “hold,” and 1 rating it as “sell.”
The public float for BMY is 2.03B and currently, short sellers hold a 1.23% ratio of that float. The average trading volume of BMY on January 20, 2025 was 10.58M shares.
BMY’s Market Performance
BMY’s stock has seen a 0.82% increase for the week, with a 0.75% rise in the past month and a 5.47% gain in the past quarter. The volatility ratio for the week is 1.80%, and the volatility levels for the past 30 days are at 1.86% for Bristol-Myers Squibb Co. The simple moving average for the past 20 days is -0.69% for BMY’s stock, with a 13.59% simple moving average for the past 200 days.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Jefferies repeating the rating for BMY by listing it as a “Buy.” The predicted price for BMY in the upcoming period, according to Jefferies is $70 based on the research report published on December 16, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see BMY reach a price target of $63. The rating they have provided for BMY stocks is “Neutral” according to the report published on December 10th, 2024.
BMY Trading at -1.80% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.84% of loss for the given period.
Volatility was left at 1.86%, however, over the last 30 days, the volatility rate increased by 1.80%, as shares sank -2.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.51% upper at present.
During the last 5 trading sessions, BMY rose by +0.82%, which changed the moving average for the period of 200-days by +6.73% in comparison to the 20-day moving average, which settled at $56.68. In addition, Bristol-Myers Squibb Co saw -0.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from Holzer Phil M, who sale 700 shares at the price of $55.62 back on Nov 04 ’24. After this action, Holzer Phil M now owns 11,760 shares of Bristol-Myers Squibb Co, valued at $38,930 using the latest closing price.
Hirawat Samit, the EVP,Chief Med.Offr.,Drug Dev. of Bristol-Myers Squibb Co, purchase 1,830 shares at $54.67 during a trade that took place back on Nov 01 ’24, which means that Hirawat Samit is holding 62,109 shares at $100,055 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.7 for the gross margin
The net margin for Bristol-Myers Squibb Co stands at -0.15. The total capital return value is set at 0.15. Equity return is now at value -31.46, with -7.85 for asset returns.
Based on Bristol-Myers Squibb Co (BMY), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 3.0. The interest coverage ratio of the stock is 5.84.
Currently, EBITDA for the company is 19.42 billion with net debt to EBITDA at 8.6. When we switch over and look at the enterprise to sales, we see a ratio of 3.32. The receivables turnover for the company is 3.18for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.24.
Conclusion
In conclusion, Bristol-Myers Squibb Co (BMY) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
